Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning session, 77 companies made new 52-week lows.
B of A Securities Downgrades Amedisys to Neutral, Announces $220 Price Target
B of A Securities downgrades Amedisys (NASDAQ:AMED) from Buy to Neutral and announces $220 price target.
Amedisys Sees FY21 Core Adj. EPS $6.37-$6.49, Adj. Service Revenue $2.23B-$2.245B; Says ‘our Hospice segment is behind in both admission and average daily census growth’
Updated 2021 Guidance
While our performance in the first half of 2021 has produced strong EBITDA and expanded margins, our Hospice segment is behind in both admission and average daily census growth. The COVID-19
Amedisys Q2 EPS $2.43 Beats $1.67 Estimate, Sales $564.20M Miss $566.19M Estimate
Amedisys (NASDAQ:AMED) reported quarterly earnings of $2.43 per share which beat the analyst consensus estimate of $1.67 by 45.51 percent. This is a 81.34 percent increase over earnings of $1.34 per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Amedisys Announces Agreement to Acquire Contessa Health, Creating a Comprehensive Home Healthcare Delivery Platform
Amedisys, Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, today announced that it has signed a definitive agreement to acquire Contessa Health, a leader in hospital-at-home and skilled